PTC Therapeutics(PTCT)
Focus: PTC Therapeutics is a public biotech company focused on small molecules and gene therapy for rare genetic disorders, with a market presence anchored by the commercial success of EMFLAZA in Duchenne muscular dystrophy. The company operates as a mid-cap biotech with diversified pipeline programs targeting neuromuscular, metabolic, and genetic diseases.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
43+24 this month
Hot — 44 jobs added in 30d
Net +24 (44 new, 20 removed). Aggressive expansion phase.
Should You Work at PTC Therapeutics?
AI assessmentStrong hiring momentum and cash position make this a viable career move for Commercial and Clinical Development professionals betting on pipeline catalysts, but the 2026 EMFLAZA cliff is a significant near-term headwind requiring pipeline vindication.
Why Work Here
- Commercial infrastructure is scaling aggressively with 19 open roles in Commercial (51% of hiring), indicating market expansion opportunity and career advancement velocity in go-to-market roles.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$938M
Key Products
$15M Part DDeclining
Peak
Help build intelligence for PTC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.